Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Patterns of increases in interleukin-6 and C-reactive protein as predictors for white matter injury in preterm infants.

Authors: Inomata, Kei  Mizobuchi, Masami  Tanaka, Satoshi  Iwatani, Sota  Sakai, Hitomi  Yoshimoto, Seiji  Nakao, Hideto 
Citation: Inomata K, etal., Pediatr Int. 2014 Dec;56(6):851-5. doi: 10.1111/ped.12376. Epub 2014 Nov 25.
Pubmed: (View Article at PubMed) PMID:24832219
DOI: Full-text: DOI:10.1111/ped.12376

BACKGROUND: The aim of this study was to determine whether patterns of increases in serum interleukin-6 (IL-6) and C-reactive protein (CRP) levels at birth were associated with the development of white matter injury (WMI) in preterm infants with a fetal inflammatory response (FIR).
METHODS: One hundred infants who were born at <32 weeks gestation and had funisitis, as determined by histological evidence of FIR, were studied. Infants were divided into four groups according to IL-6 and CRP levels at birth, with cut-off values of 200¿pg/mL and 0.4¿mg/dL, respectively. We compared the incidence of WMI, determined by MRI at term-equivalent age, among these groups.
RESULTS: The number of infants in each group was 12, 43, 0, and 45 in the high IL-6 and high CRP (HH) group, high IL-6 and low CRP (HL) group, low IL-6 and high CRP (LH) group, and low IL-6 and low CRP (LL) group, respectively. The incidence of WMI was significantly higher in the HH group than in the HL group and LL group (83%, 40%, and 34%, respectively). Multiple logistic regression analysis revealed that a combined elevation in IL-6 and CRP levels was an independent predictor for the development of WMI (odds ratio, 8.3).
CONCLUSION: A combined elevation in serum IL-6 and CRP levels at birth was associated with the development of WMI in preterm infants with FIR.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 12801490
Created: 2017-04-04
Species: All species
Last Modified: 2017-04-04
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.